Founded in 1988 in Istanbul, Turkey, Erdem Hospital is a multidisciplinary medical network specializing in advanced surgical ...

A supplement succeeds when it fits your life. PhenQ is meant to be simple: one capsule with breakfast, one with lunch.

An audio replay of the call will be available through Friday, August 29th, 2025, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and by ...

Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its ...

Discover how CrazyBulk’s legal bodybuilding supplements can enhance muscular endurance, boost strength, and speed up recovery. Learn optimal stacks, training integration tips, and where to buy ...

As part of the partnership, BioCardia has licensed global exclusive rights to CART-Tech intellectual property for the fields of biotherapeutic intervention. CART-Tech has licensed global exclusive ...

“We are honored to work with the scientific and clinical experts at MSK Therapeutics Accelerator,” stated Dr. William V. Williams, BriaCell’s President and CEO. “MSK’s deep expertise in cancer therapy ...

LIXTE will continue to closely monitor developments in the digital asset space and retains the flexibility to adjust its holdings. The Company intends to hold all cryptocurrency assets with a fully ...

Last year, KFSHRC celebrated a major milestone by completing more than 500 paired kidney transplants since the program was launched in 2011. Since launching its organ transplantation program in 1981, ...

EMERYVILLE, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its 2025 second quarter and year to date financial results and ...

Event: H.C. Wainwright 27 th Annual Global Investment Conference Location: New York, NY Date and Presentation Time: 12:30 PM Eastern Time on September 10, 2025 Event Format: Presentations and 1-on-1 ...

X4 expects to use the net proceeds from the financing for continued development towards a potential additional approval of mavorixafor in chronic neutropenia in addition to the commercialization of ...